SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...
Novo Nordisk's GLP-1 receptor agonist semaglutide ... better than placebo at resolving MASH and improving liver fibrosis, meeting its primary efficacy objectives. Analysts have suggested that ...
Investor's Business Daily on MSN6d
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk BeatViking Therapeutics reported promising early results for its experimental obesity pill, with increased weight loss at higher ...
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...
Medpage Today on MSN3d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
For high-profile biotech Viking Therapeutics (NASDAQ: VKTX), Monday was very much a good news/bad news kind of day. The ...
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $159.43, a high estimate of $160.00 ...
U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...
The Motley Fool on MSN1d
Is Viking Therapeutics a Buy on the Dip?Novo Nordisk's involve the GLP-1 pathway ... which was evident at the recent ObesityWeek 2024, an annual meeting highlighting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback